塞替派在血液淋巴系统肿瘤和造血干细胞移植中临床应用的中国专家共识(2020年版)  

Chinese expert consensus on the clinical application of thiotepa in hematological and lymphatic system tumors and hematopoietic stem cell transplantation(2020 version)

作　　者：无 张薇[3] 马军[4] 沈志祥(指导)[5] 无;Zhang Wei;Ma Jun(Chinese Society of Clinical Oncology(CSCO)Anti-Leukemia Alliance;Chinese Society of Clinical Oncology(CSCO)Anti-Lymphoma Alliance;Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100005,China;Harbin Institute of Hematology&Oncology,Harbin 150010,China)

机构地区：[1]中国临床肿瘤学会(CSCO)抗淋巴瘤联盟 [2]中国临床肿瘤学会(CSCO)抗白血病联盟 [3]北京协和医院血液内科,100005 [4]哈尔滨血液病肿瘤研究所,150010 [5]上海交通大学医学院附属瑞金医院

出　　处：《白血病．淋巴瘤》2020年第9期513-518,共6页Journal of Leukemia & Lymphoma

摘　　要：塞替派是一种烷化剂,目前已被广泛用于多种淋巴造血系统疾病,包括异基因造血干细胞移植预处理、自体造血干细胞移植预处理、原发中枢神经系统淋巴瘤和多种淋巴造血系统疾病的化疗。但是,2019年塞替派在我国重新上市之后,临床医生用药经验较少。基于塞替派目前在我国临床应用的结果,结合国内外相关文献报道,共识专家组成员讨论制定了塞替派在血液淋巴系统肿瘤和造血干细胞移植中临床应用的中国专家共识。Thiotepa is an alkylating agent that has been widely used in a variety of lymphohematopoietic diseases,including pretreatment for allogeneic hematopoietic stem cell transplantation,pretreatment for autologous hematopoietic stem cell transplantation,primary central nervous system lymphoma and chemotherapy for lymphohematopoietic diseases.However,thiotepa was re-listed in China until 2019,and most physicians has little clinical experience on the use of this agent.Based on the results of the clinical application of thiotepa in China,and the reports in the relevant domestic and foreign literature,the Chinese hematology and oncology experts developed the Chinese expert consensus on the clinical application of thiotepa in hematological and lymphatic system tumors and hematopoietic stem cell transplantation.

关 键 词：白血病 急性 重型Β地中海贫血 原发中枢神经系统淋巴瘤 淋巴瘤 非霍奇金 造血干细胞移植 塞替派 

分 类 号：R733.1[医药卫生—肿瘤] R457.7[医药卫生—临床医学]